OncoSil Medical (ASX:OSL) has announced that two key treatment centres have treated their first commercial patients with the OncoSil device, which is a targeted radioactive isotope.
This milestone has been achieved with the first patient treated with the device in the Middle East, and the first patient treatment in Spain at the Clinica Universidad de Navarra.
The device is intended to deliver more concentrated and localised beta radiation compared to external beam radiation and has received CE Marking, Breakthrough Device Designation in the European Union and the United Kingdom, and Humanitarian Use Designation (HUD) in the United States for the treatment of unresectable bile duct cancer.
Pancreatic cancer is typically diagnosed at a later stage with a poor prognosis for long-term survival, and the estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds $3B.